Ignite Creation Date:
2025-12-24 @ 5:21 PM
Ignite Modification Date:
2025-12-27 @ 6:51 PM
Study NCT ID:
NCT00820950
Status:
COMPLETED
Last Update Posted:
2022-02-08
First Post:
2009-01-08
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D011565', 'term': 'Psoriasis'}], 'ancestors': [{'id': 'D017444', 'term': 'Skin Diseases, Papulosquamous'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C540383', 'term': 'ruxolitinib'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'medinfo@incyte.com', 'phone': '1.855.463.3463', 'title': 'Incyte Corporation Call Center (US)', 'organization': 'Incyte'}, 'certainAgreement': {'otherDetails': 'Clinical Study Agreement', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'Up to approximately 2 months', 'description': 'Adverse Events were reported at the participant level, not the treatment level within each cohort.', 'eventGroups': [{'id': 'EG000', 'title': 'Part 1 Cohort A: Ruxolitinib 0.5% Cream vs. Vehicle Cream', 'description': 'Ruxolitinib 0.5% vs. vehicle cream once a day for 28 days', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 6, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Part 1 Cohort B: Ruxolitinib 1.0% Cream vs. Vehicle Cream', 'description': 'Ruxolitinib 1.0% cream once a day for 28 days', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 1, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'Part 1 Cohort C: Ruxolitinib 1.5% Cream vs. Vehicle Cream', 'description': 'Ruxolitinib 1.5% vs. vehicle cream twice a day for 28 days', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 5, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': 'Part 2 Cohort D: Ruxolitinib vs. Calcipotriene (Dovonex®)', 'description': 'Ruxolitinib up to 1.5% versus Calcipotriene (Dovonex®) 0.005% cream applied twice a day for 28 days', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 4, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG004', 'title': 'Part 2 Cohort E: Ruxolitinib vs. Betamethasone Dipropionate (Diprolene® AF)', 'description': 'Part 2 INCB018424, up to 1.5% cream versus Betamethasone Dipropionate (Diprolene® AF) 0.05% cream applied twice a day for 28 days', 'otherNumAtRisk': 5, 'deathsNumAtRisk': 5, 'otherNumAffected': 2, 'seriousNumAtRisk': 5, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG005', 'title': 'Total', 'description': 'Total', 'otherNumAtRisk': 29, 'deathsNumAtRisk': 29, 'otherNumAffected': 18, 'seriousNumAtRisk': 29, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'APPLICATION SITE REACTION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'ATRIOVENTRICULAR BLOCK', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'BLOOD CREATINE PHOSPHOKINASE INCREASED', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'BLOOD GLUCOSE INCREASED', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'CONTUSION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'DRY SKIN', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 3, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 5, 'numAffected': 3}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'ELECTROCARDIOGRAM QT CORRECTED INTERVAL PROLONGED', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'ELECTROCARDIOGRAM QT INTERVAL ABNORMAL', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'ELECTROCARDIOGRAM QT PROLONGED', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'ELECTROCARDIOGRAM T WAVE ABNORMAL', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'ERYTHEMA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 3, 'numAffected': 2}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'FEELING COLD', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'GAMMA-GLUTAMYLTRANSFERASE INCREASED', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 3, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 3, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'HAEMATOCRIT DECREASED', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'HAEMOGLOBIN DECREASED', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'HEADACHE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'NASOPHARYNGITIS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'PAIN', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'PROCEDURAL PAIN', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'PRURITUS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'RASH PRURITIC', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'RETICULOCYTE COUNT INCREASED', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'SINUS BRADYCARDIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'SKIN EXFOLIATION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 4, 'numAffected': 2}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'SKIN IRRITATION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'SUNBURN', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'UPPER RESPIRATORY TRACT INFECTION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}, {'term': 'URINE KETONE BODY PRESENT', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 29, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 9'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Change in Target Lesion Individual Component Scores for Erythema, Scaling and Thickness Compared to Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '5', 'groupId': 'OG008'}, {'value': '5', 'groupId': 'OG009'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1 Cohort A: Vehicle Cream', 'description': 'Vehicle cream was applied once a day for 28 days'}, {'id': 'OG001', 'title': 'Part 1 Cohort A: Ruxolitinib 0.5% Cream', 'description': 'Ruxolitinib 0.5% once a day for 28 days'}, {'id': 'OG002', 'title': 'Part 1 Cohort B: Vehicle Cream', 'description': 'Vehicle cream was applied once a day for 28 days'}, {'id': 'OG003', 'title': 'Part 1 Cohort B: Ruxolitinib 1.0% Cream', 'description': 'Ruxolitinib 1.0% cream once a day for 28 days'}, {'id': 'OG004', 'title': 'Part 1 Cohort C: Vehicle Cream', 'description': 'Vehicle cream was applied twice a day for 28 days'}, {'id': 'OG005', 'title': 'Part 1 Cohort C: Ruxolitinib 1.5% Cream', 'description': 'Ruxolitinib 1.5% twice a day for 28 days'}, {'id': 'OG006', 'title': 'Part 2 Cohort D: INCB18424', 'description': 'up to 1.5% Ruxolitinib cream was applied twice a day'}, {'id': 'OG007', 'title': 'Part 2 Cohort D: Calcipotriene (Dovonex®)', 'description': 'Calcipotriene (Dovonex®) 0.005% cream was applied twice a day'}, {'id': 'OG008', 'title': 'Part 2 Cohort E: INCB18424', 'description': 'up to 1.5% Ruxolitinib cream was applied twice a day'}, {'id': 'OG009', 'title': 'Part 2 Cohort E: Betamethasone Dipropionate (Diprolene® AF)', 'description': 'Betamethasone Dipropionate (Diprolene® AF) 0.05% cream was applied twice a day for 28 days'}], 'classes': [{'title': 'Day 8 - Erythema', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}, {'value': '4', 'groupId': 'OG008'}, {'value': '4', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '-0.5', 'spread': '0.84', 'groupId': 'OG000'}, {'value': '-0.5', 'spread': '0.55', 'groupId': 'OG001'}, {'value': '-0.8', 'spread': '0.41', 'groupId': 'OG002'}, {'value': '-1.0', 'spread': '0.63', 'groupId': 'OG003'}, {'value': '-0.7', 'spread': '0.82', 'groupId': 'OG004'}, {'value': '-1.2', 'spread': '0.75', 'groupId': 'OG005'}, {'value': '-1.2', 'spread': '1.10', 'groupId': 'OG006'}, {'value': '-0.8', 'spread': '0.84', 'groupId': 'OG007'}, {'value': '-1.0', 'spread': '0.82', 'groupId': 'OG008'}, {'value': '-1.3', 'spread': '0.96', 'groupId': 'OG009'}]}]}, {'title': 'Day 8 - Scaling', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '5', 'groupId': 'OG008'}, {'value': '5', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '-0.2', 'spread': '0.41', 'groupId': 'OG000'}, {'value': '-0.2', 'spread': '0.41', 'groupId': 'OG001'}, {'value': '0.0', 'spread': '0.00', 'groupId': 'OG002'}, {'value': '-0.2', 'spread': '0.41', 'groupId': 'OG003'}, {'value': '-0.7', 'spread': '0.82', 'groupId': 'OG004'}, {'value': '-1.2', 'spread': '0.41', 'groupId': 'OG005'}, {'value': '-0.6', 'spread': '0.89', 'groupId': 'OG006'}, {'value': '-0.6', 'spread': '0.55', 'groupId': 'OG007'}, {'value': '-0.8', 'spread': '0.50', 'groupId': 'OG008'}, {'value': '-0.8', 'spread': '0.50', 'groupId': 'OG009'}]}]}, {'title': 'Day 8 - Thickness', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}, {'value': '4', 'groupId': 'OG008'}, {'value': '4', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '-0.7', 'spread': '1.03', 'groupId': 'OG000'}, {'value': '-0.7', 'spread': '1.03', 'groupId': 'OG001'}, {'value': '-0.2', 'spread': '0.41', 'groupId': 'OG002'}, {'value': '-0.3', 'spread': '0.52', 'groupId': 'OG003'}, {'value': '-0.3', 'spread': '0.52', 'groupId': 'OG004'}, {'value': '-0.8', 'spread': '0.75', 'groupId': 'OG005'}, {'value': '-0.4', 'spread': '0.89', 'groupId': 'OG006'}, {'value': '-0.6', 'spread': '0.55', 'groupId': 'OG007'}, {'value': '-0.5', 'spread': '0.58', 'groupId': 'OG008'}, {'value': '-0.8', 'spread': '0.96', 'groupId': 'OG009'}]}]}, {'title': 'Day 15 - Erythema', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}, {'value': '5', 'groupId': 'OG008'}, {'value': '5', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '-0.7', 'spread': '0.82', 'groupId': 'OG000'}, {'value': '-0.7', 'spread': '0.82', 'groupId': 'OG001'}, {'value': '-0.8', 'spread': '0.75', 'groupId': 'OG002'}, {'value': '-1.0', 'spread': '0.63', 'groupId': 'OG003'}, {'value': '-0.5', 'spread': '0.84', 'groupId': 'OG004'}, {'value': '-1.2', 'spread': '0.98', 'groupId': 'OG005'}, {'value': '-1.0', 'spread': '0.71', 'groupId': 'OG006'}, {'value': '-0.8', 'spread': '0.45', 'groupId': 'OG007'}, {'value': '-1.0', 'spread': '1.00', 'groupId': 'OG008'}, {'value': '-1.2', 'spread': '0.84', 'groupId': 'OG009'}]}]}, {'title': 'Day 15 - Scaling', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}, {'value': '5', 'groupId': 'OG008'}, {'value': '5', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '-0.3', 'spread': '0.52', 'groupId': 'OG000'}, {'value': '-0.3', 'spread': '0.52', 'groupId': 'OG001'}, {'value': '-0.2', 'spread': '0.75', 'groupId': 'OG002'}, {'value': '-0.3', 'spread': '0.82', 'groupId': 'OG003'}, {'value': '-0.7', 'spread': '0.82', 'groupId': 'OG004'}, {'value': '-1.0', 'spread': '0.00', 'groupId': 'OG005'}, {'value': '-0.2', 'spread': '0.84', 'groupId': 'OG006'}, {'value': '-0.4', 'spread': '0.55', 'groupId': 'OG007'}, {'value': '-0.8', 'spread': '0.45', 'groupId': 'OG008'}, {'value': '-1.2', 'spread': '0.45', 'groupId': 'OG009'}]}]}, {'title': 'Day 15 - Thickness', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}, {'value': '5', 'groupId': 'OG008'}, {'value': '5', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '-0.3', 'spread': '0.52', 'groupId': 'OG000'}, {'value': '-0.3', 'spread': '0.52', 'groupId': 'OG001'}, {'value': '-0.2', 'spread': '0.41', 'groupId': 'OG002'}, {'value': '-0.3', 'spread': '0.52', 'groupId': 'OG003'}, {'value': '-0.5', 'spread': '0.55', 'groupId': 'OG004'}, {'value': '-0.8', 'spread': '0.41', 'groupId': 'OG005'}, {'value': '-0.6', 'spread': '1.14', 'groupId': 'OG006'}, {'value': '-0.8', 'spread': '0.84', 'groupId': 'OG007'}, {'value': '-0.6', 'spread': '1.14', 'groupId': 'OG008'}, {'value': '-0.6', 'spread': '0.89', 'groupId': 'OG009'}]}]}, {'title': 'Day 22 - Erythema', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}, {'value': '5', 'groupId': 'OG008'}, {'value': '5', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '-0.8', 'spread': '0.84', 'groupId': 'OG000'}, {'value': '-1.0', 'spread': '0.71', 'groupId': 'OG001'}, {'value': '-1.0', 'spread': '0.63', 'groupId': 'OG002'}, {'value': '-1.5', 'spread': '0.84', 'groupId': 'OG003'}, {'value': '-0.3', 'spread': '0.82', 'groupId': 'OG004'}, {'value': '-1.2', 'spread': '0.98', 'groupId': 'OG005'}, {'value': '-1.8', 'spread': '1.30', 'groupId': 'OG006'}, {'value': '-1.0', 'spread': '1.00', 'groupId': 'OG007'}, {'value': '-1.4', 'spread': '0.89', 'groupId': 'OG008'}, {'value': '-1.6', 'spread': '0.55', 'groupId': 'OG009'}]}]}, {'title': 'Day 22 - Scaling', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}, {'value': '5', 'groupId': 'OG008'}, {'value': '5', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '0.55', 'groupId': 'OG000'}, {'value': '-0.6', 'spread': '0.55', 'groupId': 'OG001'}, {'value': '-0.5', 'spread': '0.55', 'groupId': 'OG002'}, {'value': '-0.8', 'spread': '0.75', 'groupId': 'OG003'}, {'value': '-0.5', 'spread': '0.84', 'groupId': 'OG004'}, {'value': '-1.2', 'spread': '0.41', 'groupId': 'OG005'}, {'value': '-0.6', 'spread': '1.14', 'groupId': 'OG006'}, {'value': '-0.6', 'spread': '0.89', 'groupId': 'OG007'}, {'value': '-0.8', 'spread': '0.45', 'groupId': 'OG008'}, {'value': '-1.0', 'spread': '0.71', 'groupId': 'OG009'}]}]}, {'title': 'Day 22 - Thickness', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}, {'value': '5', 'groupId': 'OG008'}, {'value': '5', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '-0.2', 'spread': '1.10', 'groupId': 'OG000'}, {'value': '-0.6', 'spread': '0.89', 'groupId': 'OG001'}, {'value': '-0.3', 'spread': '0.52', 'groupId': 'OG002'}, {'value': '-0.5', 'spread': '0.84', 'groupId': 'OG003'}, {'value': '-0.8', 'spread': '0.75', 'groupId': 'OG004'}, {'value': '-1.2', 'spread': '0.75', 'groupId': 'OG005'}, {'value': '-1.0', 'spread': '1.00', 'groupId': 'OG006'}, {'value': '-0.8', 'spread': '0.45', 'groupId': 'OG007'}, {'value': '-1.0', 'spread': '0.71', 'groupId': 'OG008'}, {'value': '-0.8', 'spread': '0.84', 'groupId': 'OG009'}]}]}, {'title': 'Day 28 - Erythema', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}, {'value': '5', 'groupId': 'OG008'}, {'value': '5', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '-0.6', 'spread': '0.55', 'groupId': 'OG000'}, {'value': '-0.4', 'spread': '0.55', 'groupId': 'OG001'}, {'value': '-1.2', 'spread': '0.41', 'groupId': 'OG002'}, {'value': '-1.7', 'spread': '0.52', 'groupId': 'OG003'}, {'value': '-0.5', 'spread': '0.55', 'groupId': 'OG004'}, {'value': '-1.0', 'spread': '0.63', 'groupId': 'OG005'}, {'value': '-1.4', 'spread': '1.14', 'groupId': 'OG006'}, {'value': '-1.2', 'spread': '0.84', 'groupId': 'OG007'}, {'value': '-1.2', 'spread': '0.84', 'groupId': 'OG008'}, {'value': '-1.8', 'spread': '0.84', 'groupId': 'OG009'}]}]}, {'title': 'Day 28 - Scaling', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}, {'value': '5', 'groupId': 'OG008'}, {'value': '5', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '-0.2', 'spread': '0.45', 'groupId': 'OG000'}, {'value': '-0.4', 'spread': '0.55', 'groupId': 'OG001'}, {'value': '-0.7', 'spread': '0.52', 'groupId': 'OG002'}, {'value': '-1.0', 'spread': '0.63', 'groupId': 'OG003'}, {'value': '-0.5', 'spread': '0.55', 'groupId': 'OG004'}, {'value': '-1.2', 'spread': '0.41', 'groupId': 'OG005'}, {'value': '-0.8', 'spread': '1.10', 'groupId': 'OG006'}, {'value': '-0.8', 'spread': '0.84', 'groupId': 'OG007'}, {'value': '-0.8', 'spread': '0.45', 'groupId': 'OG008'}, {'value': '-1.2', 'spread': '0.84', 'groupId': 'OG009'}]}]}, {'title': 'Day 28 - Thickness', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}, {'value': '5', 'groupId': 'OG008'}, {'value': '5', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '0.55', 'groupId': 'OG000'}, {'value': '-0.2', 'spread': '0.45', 'groupId': 'OG001'}, {'value': '-0.3', 'spread': '0.52', 'groupId': 'OG002'}, {'value': '-1.0', 'spread': '0.63', 'groupId': 'OG003'}, {'value': '-1.2', 'spread': '0.75', 'groupId': 'OG004'}, {'value': '-1.5', 'spread': '0.55', 'groupId': 'OG005'}, {'value': '-1.0', 'spread': '1.00', 'groupId': 'OG006'}, {'value': '-1.0', 'spread': '0.00', 'groupId': 'OG007'}, {'value': '-1.0', 'spread': '0.71', 'groupId': 'OG008'}, {'value': '-1.2', 'spread': '0.45', 'groupId': 'OG009'}]}]}, {'title': 'Day 56/ET - Erythema', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '5', 'groupId': 'OG008'}, {'value': '5', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '-0.5', 'spread': '1.05', 'groupId': 'OG000'}, {'value': '-0.3', 'spread': '0.52', 'groupId': 'OG001'}, {'value': '0.0', 'spread': '0.63', 'groupId': 'OG002'}, {'value': '-0.2', 'spread': '0.41', 'groupId': 'OG003'}, {'value': '-0.5', 'spread': '0.84', 'groupId': 'OG004'}, {'value': '-0.5', 'spread': '0.84', 'groupId': 'OG005'}, {'value': '-1.0', 'spread': '0.63', 'groupId': 'OG006'}, {'value': '-1.2', 'spread': '1.47', 'groupId': 'OG007'}, {'value': '0.2', 'spread': '0.84', 'groupId': 'OG008'}, {'value': '-0.6', 'spread': '0.55', 'groupId': 'OG009'}]}]}, {'title': 'Day 56/ET - Scaling', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '5', 'groupId': 'OG008'}, {'value': '5', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '-0.2', 'spread': '0.41', 'groupId': 'OG000'}, {'value': '-0.2', 'spread': '0.41', 'groupId': 'OG001'}, {'value': '0.3', 'spread': '0.82', 'groupId': 'OG002'}, {'value': '0.7', 'spread': '0.82', 'groupId': 'OG003'}, {'value': '-0.7', 'spread': '0.82', 'groupId': 'OG004'}, {'value': '-0.7', 'spread': '0.82', 'groupId': 'OG005'}, {'value': '-0.8', 'spread': '0.75', 'groupId': 'OG006'}, {'value': '-0.7', 'spread': '1.21', 'groupId': 'OG007'}, {'value': '-0.2', 'spread': '0.84', 'groupId': 'OG008'}, {'value': '-0.4', 'spread': '0.89', 'groupId': 'OG009'}]}]}, {'title': 'Day 56/ET - Thickness', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '5', 'groupId': 'OG008'}, {'value': '5', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '-0.3', 'spread': '0.52', 'groupId': 'OG000'}, {'value': '-0.3', 'spread': '0.52', 'groupId': 'OG001'}, {'value': '0.0', 'spread': '0.75', 'groupId': 'OG002'}, {'value': '0.2', 'spread': '0.75', 'groupId': 'OG003'}, {'value': '-0.7', 'spread': '1.03', 'groupId': 'OG004'}, {'value': '-0.8', 'spread': '0.98', 'groupId': 'OG005'}, {'value': '-1.2', 'spread': '0.75', 'groupId': 'OG006'}, {'value': '-1.0', 'spread': '0.63', 'groupId': 'OG007'}, {'value': '0.0', 'spread': '0.71', 'groupId': 'OG008'}, {'value': '-0.4', 'spread': '0.55', 'groupId': 'OG009'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Days 8, 15, 22, 28 and 56', 'description': 'The investigator assessed the severity of the clinical signs erythema, scaling, and thickness for each test site by using a 5-point scale from 0 (no evidence) to 4.0 (severe).', 'unitOfMeasure': 'Scores on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Intent-to-Treat (ITT) population; 1 subject in Cohort A discontinued due to a protocol violation (Day 28 visit was late, because subject was on vacation) and 1 subject in Cohort D discontinued due to other reason (scheduling conflicts).'}, {'type': 'PRIMARY', 'title': 'Change in Target Lesion TOTAL Score (Sum of Erythema + Scaling + Thickness) Compared to Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '5', 'groupId': 'OG008'}, {'value': '5', 'groupId': 'OG009'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1 Cohort A: Vehicle', 'description': 'placebo cream'}, {'id': 'OG001', 'title': 'Part 1 Cohort A: Ruxolitinib 0.5% Cream vs. Vehicle Cream', 'description': 'Ruxolitinib 0.5% vs. vehicle cream once a day for 28 days'}, {'id': 'OG002', 'title': 'Part 1 Cohort B: Vehicle', 'description': 'Placebo cream'}, {'id': 'OG003', 'title': 'Part 1 Cohort B: Ruxolitinib 1.0% Cream vs. Vehicle Cream', 'description': 'Ruxolitinib 1.0% cream once a day for 28 days'}, {'id': 'OG004', 'title': 'Part 1 Cohort C: Vehicle Cream', 'description': 'Vehicle Placebo cream'}, {'id': 'OG005', 'title': 'Part 1 Cohort C: Ruxolitinib 1.5% Cream vs. Vehicle Cream', 'description': 'Ruxolitinib 1.5% vs. vehicle cream twice a day for 28 days'}, {'id': 'OG006', 'title': 'Part 2 Cohort D: INCB18424', 'description': 'up to 1.5% Ruxolitinib'}, {'id': 'OG007', 'title': 'Part 2 Cohort D: Ruxolitinib vs. Calcipotriene (Dovonex®)', 'description': 'Ruxolitinib up to 1.5% versus Calcipotriene (Dovonex®) 0.005% cream applied twice a day for 28 days'}, {'id': 'OG008', 'title': 'Part 2 Cohort E: INCB18424', 'description': 'up to 1.5% Ruxolitinib cream'}, {'id': 'OG009', 'title': 'Part 2 Cohort E: Ruxolitinib vs. Betamethasone Dipropionate (Diprolene® AF)', 'description': 'Part 2 INCB018424, up to 1.5% cream versus Betamethasone Dipropionate (Diprolene® AF) 0.05% cream applied twice a day for 28 days'}], 'classes': [{'title': 'Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}, {'value': '4', 'groupId': 'OG008'}, {'value': '4', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '-1.3', 'spread': '1.97', 'groupId': 'OG000'}, {'value': '-1.3', 'spread': '1.21', 'groupId': 'OG001'}, {'value': '-1.0', 'spread': '0.63', 'groupId': 'OG002'}, {'value': '-1.7', 'spread': '1.37', 'groupId': 'OG003'}, {'value': '-1.7', 'spread': '2.07', 'groupId': 'OG004'}, {'value': '-3.2', 'spread': '1.72', 'groupId': 'OG005'}, {'value': '-2.4', 'spread': '2.70', 'groupId': 'OG006'}, {'value': '-2.2', 'spread': '1.79', 'groupId': 'OG007'}, {'value': '-2.3', 'spread': '0.96', 'groupId': 'OG008'}, {'value': '-2.8', 'spread': '1.71', 'groupId': 'OG009'}]}]}, {'title': 'Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}, {'value': '5', 'groupId': 'OG008'}, {'value': '5', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '-1.3', 'spread': '1.75', 'groupId': 'OG000'}, {'value': '-1.3', 'spread': '1.75', 'groupId': 'OG001'}, {'value': '-1.3', 'spread': '2.07', 'groupId': 'OG002'}, {'value': '-2.0', 'spread': '1.79', 'groupId': 'OG003'}, {'value': '-1.7', 'spread': '2.07', 'groupId': 'OG004'}, {'value': '-3.0', 'spread': '1.26', 'groupId': 'OG005'}, {'value': '-2.0', 'spread': '2.55', 'groupId': 'OG006'}, {'value': '-2.2', 'spread': '1.79', 'groupId': 'OG007'}, {'value': '-2.4', 'spread': '2.07', 'groupId': 'OG008'}, {'value': '-3.0', 'spread': '1.87', 'groupId': 'OG009'}]}]}, {'title': 'Day 22', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}, {'value': '5', 'groupId': 'OG008'}, {'value': '5', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '-1.4', 'spread': '1.95', 'groupId': 'OG000'}, {'value': '-2.2', 'spread': '1.79', 'groupId': 'OG001'}, {'value': '-1.8', 'spread': '0.98', 'groupId': 'OG002'}, {'value': '-3.0', 'spread': '2.00', 'groupId': 'OG003'}, {'value': '-1.7', 'spread': '2.25', 'groupId': 'OG004'}, {'value': '-3.5', 'spread': '1.76', 'groupId': 'OG005'}, {'value': '-3.6', 'spread': '3.13', 'groupId': 'OG006'}, {'value': '-2.6', 'spread': '1.82', 'groupId': 'OG007'}, {'value': '-3.2', 'spread': '1.64', 'groupId': 'OG008'}, {'value': '-3.4', 'spread': '1.67', 'groupId': 'OG009'}]}]}, {'title': 'Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}, {'value': '5', 'groupId': 'OG008'}, {'value': '5', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '-1.2', 'spread': '1.30', 'groupId': 'OG000'}, {'value': '-1.0', 'spread': '1.41', 'groupId': 'OG001'}, {'value': '-2.2', 'spread': '1.17', 'groupId': 'OG002'}, {'value': '-3.8', 'spread': '1.60', 'groupId': 'OG003'}, {'value': '-2.2', 'spread': '1.60', 'groupId': 'OG004'}, {'value': '-3.7', 'spread': '1.37', 'groupId': 'OG005'}, {'value': '-3.4', 'spread': '2.70', 'groupId': 'OG006'}, {'value': '-3.2', 'spread': '1.30', 'groupId': 'OG007'}, {'value': '-3.0', 'spread': '1.58', 'groupId': 'OG008'}, {'value': '-4.2', 'spread': '1.79', 'groupId': 'OG009'}]}]}, {'title': 'Day 56/ET', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '5', 'groupId': 'OG008'}, {'value': '5', 'groupId': 'OG009'}]}], 'categories': [{'measurements': [{'value': '-1.5', 'spread': '1.87', 'groupId': 'OG000'}, {'value': '-1.3', 'spread': '1.21', 'groupId': 'OG001'}, {'value': '0.5', 'spread': '1.87', 'groupId': 'OG002'}, {'value': '0.5', 'spread': '1.38', 'groupId': 'OG003'}, {'value': '-1.8', 'spread': '2.23', 'groupId': 'OG004'}, {'value': '-2.0', 'spread': '2.10', 'groupId': 'OG005'}, {'value': '-3.2', 'spread': '1.60', 'groupId': 'OG006'}, {'value': '-3.0', 'spread': '2.90', 'groupId': 'OG007'}, {'value': '0.0', 'spread': '2.00', 'groupId': 'OG008'}, {'value': '-1.4', 'spread': '1.67', 'groupId': 'OG009'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Days 8, 15, 22, 28 and 56', 'description': 'The total target lesion score was calculated by summing the scores for erythema, scaling, and thickness for that particular target lesion. The investigator assessed the severity of the clinical signs erythema, scaling, and thickness for each test site by using a 5-point scale from 0 (no evidence) to 4.0 (severe).', 'unitOfMeasure': 'Score on Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT population; 1 subject in Cohort A discontinued due to a protocol violation (Day 28 visit was late, because subject was on vacation) and 1 subject in Cohort D discontinued due to other reason (scheduling conflicts)'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Treatment Emergent Adverse Events', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1 Cohort A: Ruxolitinib 0.5% Cream vs. Vehicle Cream', 'description': 'Ruxolitinib 0.5% vs. vehicle cream once a day for 28 days'}, {'id': 'OG001', 'title': 'Cohort B: Ruxolitinib 1.0% Cream Versus Vehicle', 'description': 'Ruxolitinib 1.0% vs. placebo cream once a day for 28 days'}, {'id': 'OG002', 'title': 'Part 1 Cohort C: Ruxolitinib 1.5% Cream vs. Vehicle Cream', 'description': 'Ruxolitinib 1.5% vs. vehicle cream twice a day for 28 days'}, {'id': 'OG003', 'title': 'Part 2 Cohort D: Ruxolitinib vs. Calcipotriene (Dovonex®)', 'description': 'Ruxolitinib up to 1.5% versus Calcipotriene (Dovonex®) 0.005% cream applied twice a day for 28 days'}, {'id': 'OG004', 'title': 'Part 2 Cohort E: Ruxolitinib vs. Betamethasone Dipropionate (Diprolene® AF)', 'description': 'Part 2 INCB018424, up to 1.5% cream versus Betamethasone Dipropionate (Diprolene® AF) 0.05% cream applied twice a day for 28 days'}], 'classes': [{'categories': [{'measurements': [{'value': '6', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '3 months', 'description': 'A TEAE is any AE either reported for first time or worsening of a pre-existing event after first dose of study drug.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Pharmacokinetics Parameter : Skin Flux of INCB018424', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1 Cohort A: Ruxolitinib 0.5% Cream vs. Vehicle Cream', 'description': 'Ruxolitinib 0.5% vs. vehicle cream once a day for 28 days'}, {'id': 'OG001', 'title': 'Part 1 Cohort B: Ruxolitinib 1.0% Cream Versus Vehicle', 'description': 'Ruxolitinib 1.0% vs. placebo cream once a day for 28 days'}, {'id': 'OG002', 'title': 'Part 1 Cohort C: Ruxolitinib 1.5% Cream vs. Vehicle Cream', 'description': 'Ruxolitinib 1.5% vs. vehicle cream twice a day for 28 days'}, {'id': 'OG003', 'title': 'Part 2 Cohort D: Ruxolitinib vs. Calcipotriene (Dovonex®)', 'description': 'Ruxolitinib up to 1.5% versus Calcipotriene (Dovonex®) 0.005% cream applied twice a day for 28 days'}, {'id': 'OG004', 'title': 'Part 2 Cohort E: Ruxolitinib vs. Betamethasone Dipropionate (Diprolene® AF)', 'description': 'Part 2 INCB018424, up to 1.5% cream versus Betamethasone Dipropionate (Diprolene® AF) 0.05% cream applied twice a day for 28 days'}], 'classes': [{'categories': [{'measurements': [{'value': '54.2', 'spread': '40.8', 'groupId': 'OG000'}, {'value': '151', 'spread': '70', 'groupId': 'OG001'}, {'value': '422', 'spread': '200', 'groupId': 'OG002'}, {'value': '363', 'spread': '215', 'groupId': 'OG003'}, {'value': '383', 'spread': '256', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Days 8, 15, 22, and 28', 'description': 'The INCB018424 skin flux was estimated from the overall mean steady-state plasma concentrations for each participant.', 'unitOfMeasure': 'ng/cm^2/h', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Pharmacokinetics Parameter : Bioavailability of INCB018424', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 1 Cohort A: Ruxolitinib 0.5% Cream vs. Vehicle Cream', 'description': 'Ruxolitinib 0.5% vs. vehicle cream once a day for 28 days'}, {'id': 'OG001', 'title': 'Cohort B: Ruxolitinib 1.0% Cream Versus Vehicle', 'description': 'Ruxolitinib 1.0% vs. placebo cream once a day for 28 days'}, {'id': 'OG002', 'title': 'Part 1 Cohort C: Ruxolitinib 1.5% Cream vs. Vehicle Cream', 'description': 'Ruxolitinib 1.5% vs. vehicle cream twice a day for 28 days'}, {'id': 'OG003', 'title': 'Part 2 Cohort D: Ruxolitinib vs. Calcipotriene (Dovonex®)', 'description': 'Ruxolitinib up to 1.5% versus Calcipotriene (Dovonex®) 0.005% cream applied twice a day for 28 days'}, {'id': 'OG004', 'title': 'Part 2 Cohort E: Ruxolitinib vs. Betamethasone Dipropionate (Diprolene® AF)', 'description': 'Part 2 INCB018424, up to 1.5% cream versus Betamethasone Dipropionate (Diprolene® AF) 0.05% cream applied twice a day for 28 days'}], 'classes': [{'categories': [{'measurements': [{'value': '2.8', 'spread': '3.2', 'groupId': 'OG000'}, {'value': '3.0', 'spread': '1.9', 'groupId': 'OG001'}, {'value': '3.0', 'spread': '1.9', 'groupId': 'OG002'}, {'value': '2.7', 'spread': '1.1', 'groupId': 'OG003'}, {'value': '2.7', 'spread': '2.3', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Days 8, 15, 22, and 28', 'description': 'The INCB018424 bioavailability will be estimated from the overall mean steady-state plasma concentrations for each subject in this study and the estimated systemic clearance of INCB018424 following oral-dose administration in another study. Bioavailability is defined as the proportion of a drug which enters the circulation when introduced into the body and so is able to have an active effect.', 'unitOfMeasure': 'Percentage of dosage', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Change in Target Lesion Area Compared to Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '5', 'groupId': 'OG008'}, {'value': '5', 'groupId': 'OG009'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort A: Vehicle', 'description': 'Placebo cream'}, {'id': 'OG001', 'title': 'Part 1 Cohort A: Ruxolitinib 0.5% Cream vs. Vehicle Cream', 'description': 'Ruxolitinib 0.5% vs. vehicle cream once a day for 28 days'}, {'id': 'OG002', 'title': 'Cohort B: Vehicle', 'description': 'Placebo cream'}, {'id': 'OG003', 'title': 'Cohort B: Ruxolitinib 1.0% Cream Versus Vehicle', 'description': 'Ruxolitinib 1.0% vs. placebo cream once a day for 28 days'}, {'id': 'OG004', 'title': 'Cohort C: Vehicle', 'description': 'Placebo cream'}, {'id': 'OG005', 'title': 'Part 1 Cohort C: Ruxolitinib 1.5% Cream vs. Vehicle Cream', 'description': 'Ruxolitinib 1.5% vs. vehicle cream twice a day for 28 days'}, {'id': 'OG006', 'title': 'Cohort D: INCB18424', 'description': 'Ruxolitinb to 1.5%'}, {'id': 'OG007', 'title': 'Part 2 Cohort D: Ruxolitinib vs. Calcipotriene (Dovonex®)', 'description': 'Ruxolitinib up to 1.5% versus Calcipotriene (Dovonex®) 0.005% cream applied twice a day for 28 days'}, {'id': 'OG008', 'title': 'Cohort E: INCB18424', 'description': 'Ruxolitinib up to 1.5%'}, {'id': 'OG009', 'title': 'Part 2 Cohort E: Ruxolitinib vs. Betamethasone Dipropionate (Diprolene® AF)', 'description': 'Part 2 INCB018424, up to 1.5% cream versus Betamethasone Dipropionate (Diprolene® AF) 0.05% cream applied twice a day for 28 days'}], 'classes': [{'categories': [{'measurements': [{'value': '0.35', 'spread': '4.872', 'groupId': 'OG000'}, {'value': '1.53', 'spread': '9.760', 'groupId': 'OG001'}, {'value': '0.45', 'spread': '3.775', 'groupId': 'OG002'}, {'value': '-3.18', 'spread': '8.651', 'groupId': 'OG003'}, {'value': '-4.03', 'spread': '12.303', 'groupId': 'OG004'}, {'value': '-11.45', 'spread': '13.851', 'groupId': 'OG005'}, {'value': '-5.22', 'spread': '6.203', 'groupId': 'OG006'}, {'value': '-2.54', 'spread': '6.778', 'groupId': 'OG007'}, {'value': '1.53', 'spread': '1.624', 'groupId': 'OG008'}, {'value': '-0.48', 'spread': '5.892', 'groupId': 'OG009'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 28', 'description': 'Lesion area was estimated on Day 1 and Day 28 using a tracings of the lesion on transparency paper and measurement of the area.', 'unitOfMeasure': 'cm^2', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Part 1 Cohort A: Vehicle Cream', 'description': 'Vehicle cream was applied once a day for 28 days'}, {'id': 'FG001', 'title': 'Part 1 Cohort A Ruxolitinib 0.5% Cream', 'description': 'Ruxolitinib 0.5% was applied once a day for 28 days'}, {'id': 'FG002', 'title': 'Part 1 Cohort B: Vehicle Cream', 'description': 'Vehicle Cream was applied once a day for 28 days'}, {'id': 'FG003', 'title': 'Part 1 Cohort B Ruxolitinib 1.0% Cream', 'description': 'Ruxolitinib 1.0% was applied once a day for 28 days'}, {'id': 'FG004', 'title': 'Part 1 Cohort C: Vehicle Cream', 'description': 'Vehicle Cream was applied once a day for 28 days'}, {'id': 'FG005', 'title': 'Part 1 Cohort C Ruxolitinib 1.5% Cream', 'description': 'Ruxolitinib 1.5% was applied once a day for 28 days'}, {'id': 'FG006', 'title': 'Part 2 Cohort D: INCB18424', 'description': 'up to 1/5% Ruolitinib cream was applied twice a day for 28 days'}, {'id': 'FG007', 'title': 'Part 2 Cohort D Calcipotriene (Dovonex®)', 'description': 'Calcipotriene (Dovonex®) 0.005% cream was applied twice a day for 28 days'}, {'id': 'FG008', 'title': 'Part 2 Cohort E: INCB18424', 'description': 'up to 1.5% Ruxolitinib cream was applied twice a day'}, {'id': 'FG009', 'title': 'Part 2 Cohort E Betamethasone Dipropionate (Diprolene® AF)', 'description': 'Betamethasone Dipropionate (Diprolene® AF) 0.05% cream were applied twice a day for 28 days'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numUnits': '6', 'numSubjects': '6'}, {'groupId': 'FG001', 'numUnits': '6', 'numSubjects': '6'}, {'groupId': 'FG002', 'numUnits': '6', 'numSubjects': '6'}, {'groupId': 'FG003', 'numUnits': '6', 'numSubjects': '6'}, {'groupId': 'FG004', 'numUnits': '6', 'numSubjects': '6'}, {'groupId': 'FG005', 'numUnits': '6', 'numSubjects': '6'}, {'groupId': 'FG006', 'numUnits': '6', 'numSubjects': '6'}, {'groupId': 'FG007', 'numUnits': '6', 'numSubjects': '6'}, {'groupId': 'FG008', 'numUnits': '5', 'numSubjects': '5'}, {'groupId': 'FG009', 'numUnits': '5', 'numSubjects': '5'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numUnits': '5', 'numSubjects': '5'}, {'groupId': 'FG001', 'numUnits': '5', 'numSubjects': '5'}, {'groupId': 'FG002', 'numUnits': '6', 'numSubjects': '6'}, {'groupId': 'FG003', 'numUnits': '6', 'numSubjects': '6'}, {'groupId': 'FG004', 'numUnits': '6', 'numSubjects': '6'}, {'groupId': 'FG005', 'numUnits': '6', 'numSubjects': '6'}, {'groupId': 'FG006', 'numUnits': '5', 'numSubjects': '5'}, {'groupId': 'FG007', 'numUnits': '5', 'numSubjects': '5'}, {'groupId': 'FG008', 'numUnits': '5', 'numSubjects': '5'}, {'groupId': 'FG009', 'numUnits': '5', 'numSubjects': '5'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numUnits': '1', 'numSubjects': '1'}, {'groupId': 'FG001', 'numUnits': '1', 'numSubjects': '1'}, {'groupId': 'FG002', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG003', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG004', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG005', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG006', 'numUnits': '1', 'numSubjects': '1'}, {'groupId': 'FG007', 'numUnits': '1', 'numSubjects': '1'}, {'groupId': 'FG008', 'numUnits': '0', 'numSubjects': '0'}, {'groupId': 'FG009', 'numUnits': '0', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Scheduling Conflict', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '1'}, {'groupId': 'FG007', 'numSubjects': '1'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}]}]}], 'typeUnitsAnalyzed': 'Plaques', 'recruitmentDetails': 'The study was conducted at 6 study centers in the United States from 08 May 2007 to 28 April 2008. This study is completed.', 'preAssignmentDetails': 'A total of 29 participants with active but stable plaque psoriasis were enrolled in the 2 part dose escalation study; 27 participant completed the study. In Part 1, each participant treated 1 plaque with INCB018424 cream, and a matching plaque with vehicle cream. In Part 2, each participant treated 1 plaque with INCB018424 cream, and a matching plaque with a comparator drug cream.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}, {'value': '6', 'groupId': 'BG003'}, {'value': '5', 'groupId': 'BG004'}, {'value': '29', 'groupId': 'BG005'}]}], 'groups': [{'id': 'BG000', 'title': 'Part 1 Cohort A: Ruxolitinib 0.5% Cream vs. Vehicle Cream', 'description': 'Ruxolitinib 0.5% vs. vehicle cream once a day for 28 days'}, {'id': 'BG001', 'title': 'Part 1 Cohort B: Ruxolitinib 1.0% Cream vs. Vehicle Cream', 'description': 'Ruxolitinib 1.0% cream vs. vehicle cream once a day for 28 days'}, {'id': 'BG002', 'title': 'Part 1 Cohort C: Ruxolitinib 1.5% Cream vs. Vehicle Cream', 'description': 'Ruxolitinib 1.5% vs. vehicle cream twice a day for 28 days'}, {'id': 'BG003', 'title': 'Part 2 Cohort D: Ruxolitinib vs. Calcipotriene (Dovonex®)', 'description': 'Ruxolitinib up to 1.5% versus Calcipotriene (Dovonex®) 0.005% cream applied twice a day for 28 days'}, {'id': 'BG004', 'title': 'Part 2 Cohort E: Ruxolitinib vs. Betamethasone Dipropionate (Diprolene® AF)', 'description': 'Part 2 INCB018424, up to 1.5% cream versus Betamethasone Dipropionate (Diprolene® AF) 0.05% cream applied twice a day for 28 days'}, {'id': 'BG005', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '42.2', 'spread': '14.25', 'groupId': 'BG000'}, {'value': '48.8', 'spread': '10.25', 'groupId': 'BG001'}, {'value': '55.8', 'spread': '10.38', 'groupId': 'BG002'}, {'value': '50.2', 'spread': '21.13', 'groupId': 'BG003'}, {'value': '46.2', 'spread': '10.08', 'groupId': 'BG004'}, {'value': '48.7', 'spread': '13.79', 'groupId': 'BG005'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex/Gender, Customized', 'classes': [{'title': 'Male', 'categories': [{'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}, {'value': '3', 'groupId': 'BG003'}, {'value': '4', 'groupId': 'BG004'}, {'value': '20', 'groupId': 'BG005'}]}]}, {'title': 'Female', 'categories': [{'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '3', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '9', 'groupId': 'BG005'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'title': 'Asian', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}]}]}, {'title': 'White or Caucasian', 'categories': [{'measurements': [{'value': '5', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '5', 'groupId': 'BG002'}, {'value': '6', 'groupId': 'BG003'}, {'value': '5', 'groupId': 'BG004'}, {'value': '27', 'groupId': 'BG005'}]}]}, {'title': 'Other', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'title': 'Hispanic or Latino', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '3', 'groupId': 'BG005'}]}]}, {'title': 'Not Hispanic or Latino', 'categories': [{'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}, {'value': '5', 'groupId': 'BG003'}, {'value': '4', 'groupId': 'BG004'}, {'value': '26', 'groupId': 'BG005'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'ITT included all enrolled participants who received at least 1 dose of INCB018424 cream.'}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 29}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2007-05-31', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-02', 'dispFirstSubmitDate': '2010-06-17', 'completionDateStruct': {'date': '2009-04-30', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-02-07', 'studyFirstSubmitDate': '2009-01-08', 'dispFirstSubmitQcDate': '2010-06-17', 'resultsFirstSubmitDate': '2021-10-18', 'studyFirstSubmitQcDate': '2009-01-09', 'dispFirstPostDateStruct': {'date': '2010-06-22', 'type': 'ESTIMATED'}, 'lastUpdatePostDateStruct': {'date': '2022-02-08', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2022-02-07', 'studyFirstPostDateStruct': {'date': '2009-01-12', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2022-02-08', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2009-01-31', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in Target Lesion Individual Component Scores for Erythema, Scaling and Thickness Compared to Baseline', 'timeFrame': 'Baseline, Days 8, 15, 22, 28 and 56', 'description': 'The investigator assessed the severity of the clinical signs erythema, scaling, and thickness for each test site by using a 5-point scale from 0 (no evidence) to 4.0 (severe).'}, {'measure': 'Change in Target Lesion TOTAL Score (Sum of Erythema + Scaling + Thickness) Compared to Baseline', 'timeFrame': 'Baseline, Days 8, 15, 22, 28 and 56', 'description': 'The total target lesion score was calculated by summing the scores for erythema, scaling, and thickness for that particular target lesion. The investigator assessed the severity of the clinical signs erythema, scaling, and thickness for each test site by using a 5-point scale from 0 (no evidence) to 4.0 (severe).'}, {'measure': 'Number of Participants With Treatment Emergent Adverse Events', 'timeFrame': '3 months', 'description': 'A TEAE is any AE either reported for first time or worsening of a pre-existing event after first dose of study drug.'}, {'measure': 'Pharmacokinetics Parameter : Skin Flux of INCB018424', 'timeFrame': 'Days 8, 15, 22, and 28', 'description': 'The INCB018424 skin flux was estimated from the overall mean steady-state plasma concentrations for each participant.'}, {'measure': 'Pharmacokinetics Parameter : Bioavailability of INCB018424', 'timeFrame': 'Days 8, 15, 22, and 28', 'description': 'The INCB018424 bioavailability will be estimated from the overall mean steady-state plasma concentrations for each subject in this study and the estimated systemic clearance of INCB018424 following oral-dose administration in another study. Bioavailability is defined as the proportion of a drug which enters the circulation when introduced into the body and so is able to have an active effect.'}], 'secondaryOutcomes': [{'measure': 'Change in Target Lesion Area Compared to Baseline', 'timeFrame': 'Day 28', 'description': 'Lesion area was estimated on Day 1 and Day 28 using a tracings of the lesion on transparency paper and measurement of the area.'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Psoriasis']}, 'referencesModule': {'references': [{'pmid': '22281165', 'type': 'DERIVED', 'citation': 'Punwani N, Scherle P, Flores R, Shi J, Liang J, Yeleswaram S, Levy R, Williams W, Gottlieb A. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol. 2012 Oct;67(4):658-64. doi: 10.1016/j.jaad.2011.12.018. Epub 2012 Jan 24.'}]}, 'descriptionModule': {'briefSummary': 'The study is comprised of two parts. The first portion of this study will be a double-blind, Sponsor-unblinded, vehicle-controlled study with application of ruxolitinib or vehicle to paired lesions at least 15 cm apart in patients with active but stable plaque psoriasis. Part 2 of the study is a double-blind, sponsor unblinded, comparison of ruxolitinib with two FDA approved products in patients with active but stable plaque psoriasis.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Body Mass Index (BMI) of 17 to 40 kg/m2\n* Subjects must have two comparable psoriatic lesions measuring between 9 and 100 cm2 and these target lesions must be similar in size to each other, and separated by at least 15 cm.\n\nExclusion Criteria:\n\n* Subjects with lesions solely involving the palms of the hands or soles of the feet or intertriginous areas, the scalp or the face.\n* Subjects with pustular psoriasis or erythroderma.\n* Subjects currently on other topical agents or UVB therapy within 2 weeks of the first dose of study medication.\n* Subjects receiving PUVA within 4 weeks of the first dose of study medication.\n* Subjects receiving systemic retinoids, etanercept, adalimumab or efalizumab or oral immunosuppressives within 3 months prior to the first dose of study medication.\n* Subjects receiving any other biological therapy (infliximab, alefacept, abatacept, etc) within 3 months of the first dose of study medication.'}, 'identificationModule': {'nctId': 'NCT00820950', 'briefTitle': 'A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis', 'organization': {'class': 'INDUSTRY', 'fullName': 'Incyte Corporation'}, 'officialTitle': 'A Double-Blind, Vehicle-Controlled, Rising Dose, Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis', 'orgStudyIdInfo': {'id': 'INCB 18424-201'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Cohort A: INCB018424 Ruxolitinib 0.5%', 'description': 'INCB018424 Ruxolitinib 0.5% vs vehicle applied once daily for 28 days', 'interventionNames': ['Drug: Ruxolitinib phosphate cream', 'Drug: Placebo cream']}, {'type': 'EXPERIMENTAL', 'label': 'Cohort B: INCB018424 Ruxolitinib 1.0%', 'description': 'INCB018424 Ruxolitinib 1.0% vs vehicle applied once daily for 28 days', 'interventionNames': ['Drug: Placebo cream', 'Drug: Ruxolitinib phosphate cream']}, {'type': 'EXPERIMENTAL', 'label': 'Cohort C: INCB018424 Ruxolitinib 1.5%', 'description': 'INCB018424 Ruxolitinib 1.5% vs vehicle applied twice for 28 days', 'interventionNames': ['Drug: Placebo cream', 'Drug: Ruxolitinib phosphate cream']}, {'type': 'EXPERIMENTAL', 'label': 'Cohort D: 18424 Ruxolitinib vs Dovonex® calcipotriene', 'description': 'INCB018424 up to 1.5% versus Dovonex® calcipotriene 0.005% cream applied BID for 28 days', 'interventionNames': ['Drug: Dovonex® calcipotriene 0.005%']}, {'type': 'EXPERIMENTAL', 'label': 'Cohort E: 18424 Ruxolitinib vs Diprolene® AF betamethasone diproprionate', 'description': 'INCB018424 up to 1.5% versus Diprolene ® AF betamethasone dipropionate 0.05% cream applied twice a day for 28 days', 'interventionNames': ['Drug: Diprolene® AF betamethasone dipropionate 0.05% cream.']}], 'interventions': [{'name': 'Ruxolitinib phosphate cream', 'type': 'DRUG', 'otherNames': ['INCB018424'], 'description': 'Ruxolitinib phosphate cream 0.5%', 'armGroupLabels': ['Cohort A: INCB018424 Ruxolitinib 0.5%']}, {'name': 'Dovonex® calcipotriene 0.005%', 'type': 'DRUG', 'description': 'Cream applied once or twice daily for up to 56 days.', 'armGroupLabels': ['Cohort D: 18424 Ruxolitinib vs Dovonex® calcipotriene']}, {'name': 'Diprolene® AF betamethasone dipropionate 0.05% cream.', 'type': 'DRUG', 'description': 'Cream applied once or twice daily for up to 56 days', 'armGroupLabels': ['Cohort E: 18424 Ruxolitinib vs Diprolene® AF betamethasone diproprionate']}, {'name': 'Placebo cream', 'type': 'DRUG', 'description': 'Cream applied once or twice daily for 56 days', 'armGroupLabels': ['Cohort A: INCB018424 Ruxolitinib 0.5%', 'Cohort B: INCB018424 Ruxolitinib 1.0%', 'Cohort C: INCB018424 Ruxolitinib 1.5%']}, {'name': 'Ruxolitinib phosphate cream', 'type': 'DRUG', 'otherNames': ['INCB018424'], 'description': 'Ruxolitinib phosphate cream 1.0%', 'armGroupLabels': ['Cohort B: INCB018424 Ruxolitinib 1.0%']}, {'name': 'Ruxolitinib phosphate cream', 'type': 'DRUG', 'otherNames': ['INCB018424'], 'description': 'Ruxolitinib phosphate cream 1.5%', 'armGroupLabels': ['Cohort C: INCB018424 Ruxolitinib 1.5%']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Vallejo', 'state': 'California', 'country': 'United States', 'geoPoint': {'lat': 38.10409, 'lon': -122.25664}}, {'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'city': 'Rochester', 'state': 'New York', 'country': 'United States', 'geoPoint': {'lat': 43.15478, 'lon': -77.61556}}, {'city': 'Stony Brook', 'state': 'New York', 'country': 'United States', 'geoPoint': {'lat': 40.92565, 'lon': -73.14094}}, {'city': 'Portland', 'state': 'Oregon', 'country': 'United States', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'city': 'Philadelphia', 'state': 'Pennsylvania', 'country': 'United States', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}], 'overallOfficials': [{'name': 'William Williams, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Incyte Corporation'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Incyte Corporation', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}